Bullish
Pfizer's Lyme disease vaccine application validated by EMA; stock up 1.6%
Pfizer's stock rose 1.6% following the European Medicines Agency's validation of its Lyme disease vaccine application. This development is expected to bolster the company's vaccine portfolio and revenue streams.
Key points
- Pfizer's Lyme disease vaccine application validated by EMA.
- Pfizer's stock price increased by 1.6% to $27.30.
Sources
AI-generated from public news sources. Not financial advice.
